MX2018012132A - Reduccion de carga tumoral mediante administracion de antagonistas de ccr1 en combinacion con inhibidores de muerte-1 programada (pd-1) o inhibidores de ligando-1 de muerte-1 programada (pd-l1). - Google Patents
Reduccion de carga tumoral mediante administracion de antagonistas de ccr1 en combinacion con inhibidores de muerte-1 programada (pd-1) o inhibidores de ligando-1 de muerte-1 programada (pd-l1).Info
- Publication number
- MX2018012132A MX2018012132A MX2018012132A MX2018012132A MX2018012132A MX 2018012132 A MX2018012132 A MX 2018012132A MX 2018012132 A MX2018012132 A MX 2018012132A MX 2018012132 A MX2018012132 A MX 2018012132A MX 2018012132 A MX2018012132 A MX 2018012132A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- combination
- administering
- tumor burden
- reducing tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 239000012270 PD-1 inhibitor Substances 0.000 title abstract 2
- 239000012668 PD-1-inhibitor Substances 0.000 title abstract 2
- 229940121655 pd-1 inhibitor Drugs 0.000 title abstract 2
- 239000012271 PD-L1 inhibitor Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 title 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 abstract 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 abstract 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010061309 Neoplasm progression Diseases 0.000 abstract 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000002559 chemokine receptor antagonist Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 230000005751 tumor progression Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención proporciona métodos para reducir la carga tumoral, crecimiento tumoral, progreso tumoral y/o metástasis en un sujeto que padece de un cáncer de tumor sólido tal como cáncer de mama triple negativo. Los métodos incluyen administrar a un sujeto en necesidad del mismo una cantidad terapéuticamente efectiva de un inhibidor de PD-L1 o un inhibidor de PD-1 en combinación con un antagonista de receptor de quimiocina de molécula pequeña que bloquea CCR1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662319689P | 2016-04-07 | 2016-04-07 | |
PCT/US2017/026290 WO2017176965A1 (en) | 2016-04-07 | 2017-04-06 | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018012132A true MX2018012132A (es) | 2019-03-28 |
Family
ID=59999231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012132A MX2018012132A (es) | 2016-04-07 | 2017-04-06 | Reduccion de carga tumoral mediante administracion de antagonistas de ccr1 en combinacion con inhibidores de muerte-1 programada (pd-1) o inhibidores de ligando-1 de muerte-1 programada (pd-l1). |
Country Status (20)
Country | Link |
---|---|
US (2) | US10568870B2 (es) |
EP (1) | EP3439653B1 (es) |
JP (2) | JP2019510832A (es) |
KR (1) | KR102370704B1 (es) |
CN (1) | CN109310677A (es) |
AR (1) | AR108202A1 (es) |
AU (1) | AU2017246460B2 (es) |
BR (1) | BR112018070361A2 (es) |
CA (1) | CA3019391A1 (es) |
DK (1) | DK3439653T3 (es) |
ES (1) | ES2864148T3 (es) |
IL (1) | IL261998B2 (es) |
MX (1) | MX2018012132A (es) |
PL (1) | PL3439653T3 (es) |
PT (1) | PT3439653T (es) |
RU (1) | RU2745195C2 (es) |
SG (1) | SG11201808626WA (es) |
TW (1) | TWI808938B (es) |
WO (1) | WO2017176965A1 (es) |
ZA (1) | ZA201806633B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2893597C (en) | 2012-12-07 | 2021-06-29 | Chemocentryx, Inc. | Diazole lactams |
BR112017019559B1 (pt) | 2015-03-13 | 2020-08-04 | Cytomx Therapeutics, Inc | Anticorpos anti-pdl1, anticorpos anti-pdl1 ativáveis, e métodos de uso destes |
US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
PT3439653T (pt) | 2016-04-07 | 2021-03-25 | Chemocentryx Inc | Redução da carga tumoral por administração de antagonistas de ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1 |
CA3029256A1 (en) | 2016-06-27 | 2018-01-04 | Chemocentryx, Inc. | Immunomodulator compounds |
HUE054316T2 (hu) * | 2017-03-29 | 2021-08-30 | Shionogi & Co | Gyógyászati készítmény rák kezelésére |
KR20200016899A (ko) | 2017-06-01 | 2020-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항-pdl1 항체, 및 이의 이용 방법 |
IL272258B (en) | 2017-07-28 | 2022-08-01 | Chemocentryx Inc | Immunomodulator compounds |
MA49859A (fr) | 2017-08-08 | 2021-04-07 | Chemocentryx Inc | Immunomodulateurs macrocycliques |
CN111511397A (zh) * | 2017-12-22 | 2020-08-07 | 科达金尼克斯有限公司 | 具有密码子对去优化区域的重组病毒及其用于治疗癌症的用途 |
MA51232A (fr) | 2018-02-22 | 2020-10-07 | Chemocentryx Inc | Indane-amines utiles en tant qu'antagonistes de pd-l1 |
JP7329860B2 (ja) * | 2018-06-15 | 2023-08-21 | ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム | S-エクオールを用いた乳癌の治療及び予防方法 |
EP3843711A4 (en) * | 2018-08-29 | 2022-08-03 | ChemoCentryx, Inc. | METHODS OF CANCER TREATMENT WITH SMALL MOLECULE PD-L1 INHIBITORS |
TW202024638A (zh) * | 2018-09-04 | 2020-07-01 | 美商泰沙羅公司 | 治療癌症之方法 |
US20220177587A1 (en) | 2018-09-19 | 2022-06-09 | Alpine Immune Sciences, Inc. | Methods and uses of variant cd80 fusion proteins and related constructs |
KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
FI3880186T3 (fi) | 2018-11-14 | 2024-05-30 | Regeneron Pharma | PD-1-inhibiittoreiden intralesionaalinen antaminen ihosyövän hoitamiseksi |
KR20210134690A (ko) | 2019-02-28 | 2021-11-10 | 리제너론 파아마슈티컬스, 인크. | 피부 암을 치료하기 위한 pd-1 억제제의 투여 |
WO2020180727A1 (en) | 2019-03-06 | 2020-09-10 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer |
JP2022539830A (ja) | 2019-07-10 | 2022-09-13 | ケモセントリックス,インコーポレイティド | Pd-l1阻害剤としてのインダン |
GB201918692D0 (en) | 2019-12-18 | 2020-01-29 | Cambridge Entpr Ltd | Treatment and prognosis of pancreatic cancer |
TW202207940A (zh) * | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
WO2021242728A1 (en) | 2020-05-26 | 2021-12-02 | Regeneron Pharmaceuticals, Inc. | Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab |
IL300328A (en) | 2020-08-26 | 2023-04-01 | Regeneron Pharma | Methods for treating cancer by administering a PD-1 inhibitor |
CN116194142A (zh) | 2020-09-03 | 2023-05-30 | 瑞泽恩制药公司 | 通过施用pd-1抑制剂治疗癌症疼痛的方法 |
AU2021362156A1 (en) * | 2020-10-13 | 2023-06-15 | Board Of Regents, The University Of Texas System | Combinatorial immunotherapeutic methods and compositions for pancreatic ductal adenocarcinoma treatment |
AU2022242000A1 (en) | 2021-03-23 | 2023-09-14 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor |
IL310201A (en) | 2021-07-19 | 2024-03-01 | Regeneron Pharma | Combination of inhibitor-control inhibitor and oncolytic virus for cancer treatment |
WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
WO2023159102A1 (en) | 2022-02-17 | 2023-08-24 | Regeneron Pharmaceuticals, Inc. | Combinations of checkpoint inhibitors and oncolytic virus for treating cancer |
WO2023230220A2 (en) * | 2022-05-25 | 2023-11-30 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11513382A (ja) | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 5員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
DE19539091A1 (de) | 1995-10-20 | 1997-04-24 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung |
US6756385B2 (en) | 2000-07-31 | 2004-06-29 | Pfizer Inc. | Imidazole derivatives |
GT200100147A (es) | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
AU2001290258A1 (en) | 2000-09-22 | 2002-04-02 | Nihon Nohyaku Co. Ltd. | N-(4-pyrazolyl)amide derivatives, chemicals for agricultural and horticultural use, and usage of the same |
US20050256130A1 (en) | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
US7589199B2 (en) | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
US7842693B2 (en) | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
RU2342365C2 (ru) | 2003-05-01 | 2008-12-27 | Бристол-Маерс Сквибб Компани | Арилзамещенные пиразоламиды в качестве ингибиторов киназ |
CA2609051A1 (en) | 2005-05-19 | 2006-11-23 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
US7777035B2 (en) | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
NZ564258A (en) * | 2005-06-22 | 2011-02-25 | Chemocentryx Inc | Azaindazole compounds and methods of use |
FR2887450B1 (fr) | 2005-06-23 | 2007-08-24 | Rhodia Chimie Sa | Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques |
JPWO2007026834A1 (ja) | 2005-09-01 | 2009-03-12 | クミアイ化学工業株式会社 | ピラゾール誘導体及び農園芸用除草剤 |
WO2007044885A2 (en) | 2005-10-11 | 2007-04-19 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
US20090252779A1 (en) | 2006-06-22 | 2009-10-08 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
CA2675511A1 (en) | 2006-10-10 | 2008-04-17 | Amgen Inc. | N-aryl pyrazole compounds for use against diabetes |
US20100113776A1 (en) | 2006-12-14 | 2010-05-06 | Taisho Pharmaceutical Co.,Ltd. | Pyrazole derivative |
US7786157B2 (en) | 2007-03-16 | 2010-08-31 | Chemocentryx, Inc. | OXO-imidazolidines as modulators of chemokine receptors |
EP2155712B1 (en) | 2007-05-22 | 2016-09-07 | ChemoCentryx, Inc. | 3-(imidazolyl)-pyrazolo[3,4-b]pyridines |
AU2008266951B2 (en) | 2007-06-18 | 2013-12-12 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor PD-1 |
SI3184527T1 (sl) | 2007-06-22 | 2020-03-31 | Eli Lilly And Company | Spojine 2,6-diokso,-2,3-dihidro-1H-purina uporabne za zdravljenje stanj povezanih z aktivnostjo TRPA1 kanala |
KR101571176B1 (ko) | 2007-11-13 | 2015-11-23 | 다이쇼 세이야꾸 가부시끼가이샤 | 페닐피라졸 유도체 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
CA2722811C (en) | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
WO2009140519A1 (en) | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
EP2323663B1 (en) * | 2008-09-11 | 2015-02-25 | ChemoCentryx, Inc. | 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines |
DK2342226T3 (en) | 2008-09-26 | 2016-09-26 | Dana Farber Cancer Inst Inc | HUMAN ANTI-PD-1, PD-L1 AND PD-L2 ANTIBODIES AND APPLICATIONS THEREOF |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
GB0915892D0 (en) | 2009-09-10 | 2009-10-14 | Smithkline Beecham Corp | Compounds |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
EP2717895A1 (en) | 2011-06-08 | 2014-04-16 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-pd-l1 항체 및 그의 용도 |
WO2013132317A1 (en) | 2012-03-07 | 2013-09-12 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
AU2013239366A1 (en) | 2012-03-29 | 2014-10-16 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the BC loop of human PD1 |
CN104470949A (zh) | 2012-05-15 | 2015-03-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
EP2855528B1 (en) | 2012-05-31 | 2019-06-19 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
MX367436B (es) * | 2012-08-27 | 2019-08-21 | Chemocentryx Inc | Antagonistas de los receptores de quimiocina. |
CA2893597C (en) * | 2012-12-07 | 2021-06-29 | Chemocentryx, Inc. | Diazole lactams |
US9169248B2 (en) | 2012-12-21 | 2015-10-27 | Chemocentryx, Inc. | Diazole amides |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
MY183503A (en) * | 2013-07-16 | 2021-02-23 | Genentech Inc | Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
ES2827679T3 (es) | 2013-08-20 | 2021-05-24 | Merck Sharp & Dohme | Tratamiento del cáncer con una combinación de un antagonista de PD-1 y dinaciclib |
AU2014315457B2 (en) | 2013-09-04 | 2018-05-10 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
JP6474412B2 (ja) | 2013-09-06 | 2019-02-27 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | 免疫調節剤としての環式ペプチドミメティック化合物 |
ES2788848T3 (es) | 2013-09-06 | 2020-10-23 | Aurigene Discovery Tech Ltd | Derivados de 1,2,4-oxadiazol como inmunomoduladores |
SG11201601679TA (en) | 2013-09-06 | 2016-04-28 | Aurigene Discovery Tech Ltd | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
WO2015036927A1 (en) | 2013-09-10 | 2015-03-19 | Aurigene Discovery Technologies Limited | Immunomodulating peptidomimetic derivatives |
WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
CN107074945B (zh) * | 2014-05-27 | 2021-08-24 | 中央研究院 | 增进抗体功效的通用糖型的组合物及方法 |
CN106573060A (zh) * | 2014-07-15 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物 |
TN2017000084A1 (en) | 2014-09-11 | 2018-07-04 | Bristol Myers Squibb Co | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
WO2016142852A1 (en) | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators |
CA2979161A1 (en) | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
AU2016230795A1 (en) | 2015-03-10 | 2017-09-07 | Aurigene Discovery Technologies Limited | Therapeutic cyclic compounds as immunomodulators |
BR112017019307A2 (pt) | 2015-03-10 | 2018-05-02 | Aurigene Discovery Technologies Limited | compostos de 1,3,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores |
EA034708B1 (ru) | 2015-03-10 | 2020-03-10 | Ауриджен Дискавери Текнолоджис Лимитед | 1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
PT3439653T (pt) | 2016-04-07 | 2021-03-25 | Chemocentryx Inc | Redução da carga tumoral por administração de antagonistas de ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1 |
-
2017
- 2017-04-06 PT PT177798014T patent/PT3439653T/pt unknown
- 2017-04-06 BR BR112018070361A patent/BR112018070361A2/pt active Search and Examination
- 2017-04-06 TW TW106111608A patent/TWI808938B/zh active
- 2017-04-06 IL IL261998A patent/IL261998B2/en unknown
- 2017-04-06 SG SG11201808626WA patent/SG11201808626WA/en unknown
- 2017-04-06 EP EP17779801.4A patent/EP3439653B1/en active Active
- 2017-04-06 AU AU2017246460A patent/AU2017246460B2/en active Active
- 2017-04-06 PL PL17779801T patent/PL3439653T3/pl unknown
- 2017-04-06 US US15/480,992 patent/US10568870B2/en active Active
- 2017-04-06 MX MX2018012132A patent/MX2018012132A/es unknown
- 2017-04-06 JP JP2019503632A patent/JP2019510832A/ja active Pending
- 2017-04-06 ES ES17779801T patent/ES2864148T3/es active Active
- 2017-04-06 CN CN201780034790.7A patent/CN109310677A/zh active Pending
- 2017-04-06 RU RU2018138828A patent/RU2745195C2/ru active
- 2017-04-06 DK DK17779801.4T patent/DK3439653T3/da active
- 2017-04-06 WO PCT/US2017/026290 patent/WO2017176965A1/en active Application Filing
- 2017-04-06 CA CA3019391A patent/CA3019391A1/en active Pending
- 2017-04-06 KR KR1020187032233A patent/KR102370704B1/ko active IP Right Grant
- 2017-04-07 AR ARP170100898A patent/AR108202A1/es unknown
-
2018
- 2018-10-05 ZA ZA2018/06633A patent/ZA201806633B/en unknown
-
2020
- 2020-01-14 US US16/742,139 patent/US11744822B2/en active Active
-
2022
- 2022-06-07 JP JP2022092430A patent/JP2022130424A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20170290808A1 (en) | 2017-10-12 |
KR20190020291A (ko) | 2019-02-28 |
WO2017176965A1 (en) | 2017-10-12 |
BR112018070361A2 (pt) | 2019-01-29 |
DK3439653T3 (da) | 2021-03-29 |
IL261998A (en) | 2018-10-31 |
US10568870B2 (en) | 2020-02-25 |
IL261998B (en) | 2022-11-01 |
KR102370704B1 (ko) | 2022-03-03 |
PT3439653T (pt) | 2021-03-25 |
IL261998B2 (en) | 2023-03-01 |
SG11201808626WA (en) | 2018-10-30 |
ES2864148T3 (es) | 2021-10-13 |
TWI808938B (zh) | 2023-07-21 |
RU2745195C2 (ru) | 2021-03-22 |
AU2017246460B2 (en) | 2021-04-22 |
CA3019391A1 (en) | 2017-10-12 |
US11744822B2 (en) | 2023-09-05 |
EP3439653A1 (en) | 2019-02-13 |
EP3439653A4 (en) | 2019-12-04 |
RU2018138828A (ru) | 2020-05-15 |
US20200289472A1 (en) | 2020-09-17 |
ZA201806633B (en) | 2021-04-28 |
RU2018138828A3 (es) | 2020-08-12 |
PL3439653T3 (pl) | 2021-07-05 |
JP2022130424A (ja) | 2022-09-06 |
AU2017246460A1 (en) | 2018-10-25 |
JP2019510832A (ja) | 2019-04-18 |
TW201801724A (zh) | 2018-01-16 |
CN109310677A (zh) | 2019-02-05 |
EP3439653B1 (en) | 2021-01-20 |
AR108202A1 (es) | 2018-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018012132A (es) | Reduccion de carga tumoral mediante administracion de antagonistas de ccr1 en combinacion con inhibidores de muerte-1 programada (pd-1) o inhibidores de ligando-1 de muerte-1 programada (pd-l1). | |
MX2022001757A (es) | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer. | |
MX2018014435A (es) | Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer. | |
PH12020550622A1 (en) | Kras g12c inhibitors | |
PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
MX2021002804A (es) | Terapias de combinacion. | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
CR20190478A (es) | Inhibidores de pd-1/pd-l1 | |
PH12018500086A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
MX2018013983A (es) | Inhibidores g12c de kras. | |
EA201691376A1 (ru) | Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака | |
MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
NZ737399A (en) | Ccr2 modulators | |
EA201790926A1 (ru) | Комбинированное лечение злокачественного новообразования | |
NZ718190A (en) | Substituted quinazolines for inhibiting kinase activity | |
MX2021007651A (es) | Inhibidores de ezh2 para tratar linfomas. | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
MX2018001507A (es) | Composiciones y metodos para tratar cánceres asociados con la activacion del etbr. | |
MX2019010149A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
NZ724799A (en) | Compositions and methods for the treatment or prevention of neurodegenerative disorders | |
MY192305A (en) | Bipyrazole derivatives as jak inhibitors |